Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Alabama at Birmingham
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female
Any race or ethnicity
BMI \>27 kg/m2
Presence of 1 or more mild-to-moderate obesity-associated metabolic complications (i.e., Stage 1 Obesity)
You may not be if
Stable medication type and dosage for ≥3 months
If type 2 diabetes,
Currently prescribed metformin or prescribed within previous 3 months
HbA1c concentration of \>12%
Using exogenous insulin
Pregnant or lactating within the past 6 months or trying to become pregnant
Prescription for weight loss medications within the past 3 months
Severe obesity-related complications that require immediate and more intensive clinical therapy (e.g., pharmacotherapy and/or bariatric surgery) as determined by study physician and/or referring practitioner at UAB Family Medicine Clinic.
History of kidney disease that may increase the risk of lactic acidosis with metformin.
Currently prescribed the following medications that may increase the risk of lactic acidosis with metformin: acetazolamide (Diamox), dichlorphenamide (Keveyis), methazolamide, topiramate (Topamax, in Qsymia), or zonisamide (Zonegran).
Does not have a life-sustaining medical implant such as a pacemaker.
Clareo Health | Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics
